keyword
MENU ▼
Read by QxMD icon Read
search

macroprolactinoma

keyword
https://www.readbyqxmd.com/read/27908214/pregnancy-and-tumor-outcomes-in-infertile-women-with-macroprolactinoma-on-cabergoline-therapy
#1
Ashu Rastogi, Sanjay K Bhadada, Anil Bhansali
Hyperprolactinemia and prolactinomas cause infertility in significant number of women. But, pregnancy may lead to post-partum remission of hyperprolactinemia. The data on pregnancy and tumor outcome in women with macroprolactinoma conceiving on Cabergoline (CAB) therapy is increasing but still less than with Bromocriptine. We studied the incidence of fetal malformations, hyperprolactinemia and tumor course after gestation in infertile women harboring macroprolactinoma, who conceived on CAB therapy during the year 2005-2015...
December 2, 2016: Gynecological Endocrinology
https://www.readbyqxmd.com/read/27855233/a-macroprolactinoma-becoming-resistant-to-cabergoline-and-developing-atypical-pathology
#2
Emilia Sbardella, George Farah, Ahmed Fathelrahman, Simon Cudlip, Olaf Ansorge, Niki Karavitaki, Ashley B Grossman
: Pituitary adenomas are a common intracranial neoplasm, usually demonstrating a benign phenotype. They can be classified according to pathological, radiological or clinical behaviour as typical, atypical or carcinomas, invasive or noninvasive, and aggressive or nonaggressive. Prolactinomas account for 40-60% of all pituitary adenomas, with dopamine agonists representing the first-line treatment and surgery/radiotherapy reserved for drug intolerance/resistance or in neuro-ophthalmological emergencies...
2016: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/27783196/management-of-prolactinomas-a-survey-of-physicians-from-the-middle-east-and-north-africa
#3
Salem A Beshyah, Ibrahim H Sherif, Farida Chentli, Amir Hamrahian, Aly B Khalil, Hussein Raef, Mohamed El-Fikki, Selim Jambart
BACKGROUND: Prolactinomas are the commonest functional tumors of the pituitary gland. There are still controversies regarding medical therapy in specific clinical situations. Patients may be managed by different specialists in the Middle East and North Africa (MENA) region and no data exist on patterns of clinical management. OBJECTIVES: To ascertain the diagnostic and therapeutic approaches to prolactinomas among relevant professionals from the MENA region. METHODS: An online survey of a large sample of physicians was conducted...
October 25, 2016: Pituitary
https://www.readbyqxmd.com/read/27682355/surgical-outcomes-of-prolactinomas-in-recent-era-results-of-a-heterogenous-group
#4
Diane Donegan, John L D Atkinson, Mark Jentoft, Neena Natt, Tod B Nippoldt, Bradley Erickson, Fredric Meyer, Dana Erickson
OBJECT: Prolactinomas are primarily treated with medical therapy. Given the efficacy of Dopamine agonists (DA), surgery has remained a second line treatment option. Despite medical therapy, some tumors display resistance and or patients maybe intolerant of DA requiring alternative treatment options. We examined the indications, efficacy and safety of pituitary surgery for the treatment of prolactinomas. METHODS: We performed a retrospective analysis of all patients who had surgery for a prolactinoma at our institution from January 1993 to October 2014...
September 28, 2016: Endocrine Practice
https://www.readbyqxmd.com/read/27668187/approach-to-the-management-of-rare-clinical-presentations-of-macroprolactinomas-in-reproductive-aged-women
#5
Ana Espinosa De Ycaza, Alice Y Chang, Jani R Jensen, Zaraq Khan, Dana Erickson
OBJECTIVE: To describe 2 cases of macroprolactinomas with atypical presentation in women desiring pregnancy that illustrate important considerations in the management approach for macroprolactinomas in reproductive-aged women. PATIENTS: Case 1 was a 26-year-old woman referred to our institution for possible tumor resection after pituitary apoplexy during her first pregnancy. Instead, she underwent treatment with cabergoline for a year with goals of normalization of prolactin and decrease in tumor size to <1 cm before trying to conceive...
October 2015: Case Reports in Women's Health
https://www.readbyqxmd.com/read/27651307/long-term-results-of-cabergoline-therapy-for-macroprolactinomas-and-analyses-of-factors-associated-with-remission-after-withdrawal
#6
Shinya Watanabe, Hiroyoshi Akutsu, Shingo Takano, Tetsuya Yamamoto, Eiichi Ishikawa, Hiroaki Suzuki, Akira Matsumura
OBJECTIVE: Withdrawal of cabergoline is generally challenging, especially in patients with large or invasive macroprolactinomas. Therefore, we aimed to assess long-term results of cabergoline therapy for macroprolactinomas and remission achievement results after withdrawal in patients with macroprolactinomas. We also investigated clinical characteristics and factors related to remission after withdrawal. METHODS: This was an institutional review board-approved retrospective analysis...
September 21, 2016: Clinical Endocrinology
https://www.readbyqxmd.com/read/27641080/long-term-outcome-of-macroprolactinomas
#7
Lori Képénékian, Hélène Cebula, Frédéric Castinetti, Thomas Graillon, Thierry Brue, Bernard Goichot
OBJECTIVE: Management of macroprolactinomas has dramatically changed in recent decades, from surgical to medical treatment as first-line therapy, with the development of dopamine agonists (DA). But few data exist on the long-term outcome of these patients. PATIENTS AND METHODS: Retrospective descriptive multicenter study of patients with macroprolactinoma followed for at least 5 years between 1973 and 2008 at the University Hospitals of Strasbourg and Marseille...
December 2016: Annales D'endocrinologie
https://www.readbyqxmd.com/read/27525431/treatment-of-hyperprolactinaemia-reduces-total-cholesterol-and-ldl-in-patients-with-prolactinomas
#8
Verena Schwetz, Rosaria Librizzi, Christian Trummer, Georg Theiler, Claudia Stiegler, Thomas R Pieber, Barbara Obermayer-Pietsch, Stefan Pilz
Previous studies suggest that hyperprolactinaemia might have adverse effects on lipid and glucose metabolism. We therefore aimed to evaluate whether dopamine agonist treatment with cabergoline has significant effects on blood lipids, fasting glucose and HbA1c levels in patients with micro- or macroprolactinoma. In this retrospective observational study the main outcome measures are changes in parameters of glucose and lipid metabolism compared at hyperprolactinaemia and after achievement of normoprolactinaemia by cabergoline treatment...
August 15, 2016: Metabolic Brain Disease
https://www.readbyqxmd.com/read/27487374/prolactinomas-may-have-unusual-presentations-resulting-from-massive-extrasellar-tumor-extension
#9
Marise Ribeiro de Sousa Berriel, Giovanna Aparecida Balarini Lima, Alessandro Severo Alves de Melo, Maria Laura Vasconcelos Dos Santos, Hassan Rahhal, Giselle Fernandes Taboada
The purpose of this case series is to report eight patients with giant prolactinomas emphasizing presentations and a treatment complication. The study group included six men and two women. The median age was 29 years (18-54 years); median serum prolactin level was 4,562 ng/ml (1,543-18,690 ng/ml); three patients (37.5%) had panhypopituitarism; median tumor diameter was 50 mm (41-60 mm). Five patients (62.5%) had visual field defects and three had improvement during treatment; six patients (75%) reached prolactin normalization, with a median time of 10...
July 2016: Arquivos de Neuro-psiquiatria
https://www.readbyqxmd.com/read/27460005/dopamine-agonist-therapy-induces-significant-recovery-of-hpa-axis-function-in-prolactinomas-independent-of-tumor-size-a-large-single-center-experience
#10
Christine G Yedinak, Isabelle Cetas, Alp Ozpinar, Shirley McCartney, Aclan Dogan, Maria Fleseriu
Our objective was to compare prevalence and rates of recovery of hypothalamic-pituitary-adrenal axis dysfunction in prolactinoma patients before and after dopamine agonist therapy with nonfunctioning pituitary adenoma patients pre-transsphenoidal and post-transsphenoidal surgery. We retrospectively compared hypothalamic-pituitary-adrenal axis function in patients with prolactinomas naïve to dopamine agonist therapy with a cohort of nonfunctioning pituitary adenoma patients matched for gender and tumor size by classification (n = 57; 30 male/27 female; 27 microadenoma/30 macroadenoma)...
October 2016: Endocrine
https://www.readbyqxmd.com/read/27400437/topiramate-overcoming-dopamine-agonist-induced-migraine-exacerbation-and-avoiding-transsphenoidal-surgery-in-a-young-boy-with-a-macroprolactinoma
#11
André M Faria, Paula de F Presti, Durval Damiani, Nina Rosa Musolino, Malebranche B C Cunha Neto
No abstract text is available yet for this article.
July 11, 2016: Headache
https://www.readbyqxmd.com/read/27400138/ventriculitis-from-a-pituitary-prolactinoma-bacterial-or-chemical
#12
Bodiabaduge A P Jayasekera, Julie Hall, Simon Pearce, Alistair J Jenkins
We report the case of a 70-year-old man presenting with pituitary apoplexy from a macroprolactinoma and ventriculitis. It was not possible to distinguish a bacterial or chemical origin, on the basis of his clinical presentation, laboratory studies and imaging, highlighting the importance of prompt imaging and attainment of CSF cultures, in making the diagnosis.
July 11, 2016: British Journal of Neurosurgery
https://www.readbyqxmd.com/read/27130071/prolactinoma-and-pregnancy-from-the-wish-of-conception-to-lactation
#13
Dominique Maiter
Prolactinoma is a common cause of infertility in young women and treatment with dopamine agonists (DA) allows restoration of fertility in over 90% of the cases. Both bromocriptine and cabergoline have shown a good safety profile when administered during early pregnancy. In particular, data on exposure of the fetus or embryo to cabergoline during the first weeks of pregnancy have now been reported in more than 900 cases, and do indicate that cabergoline is safe in this context. There is no increase in the frequency of spontaneous miscarriage, premature delivery, multiple births or neonatal malformations, and follow-up studies of the children for up to 12years after fetal exposure to cabergoline did not show any physical or developmental abnormalities...
June 2016: Annales D'endocrinologie
https://www.readbyqxmd.com/read/26909481/prolactinomas-evolution-after-menopause
#14
MULTICENTER STUDY
Maria Susana Mallea-Gil, Marcos Manavela, Analia Alfieri, Maria Carolina Ballarino, Alberto Chervin, Karina Danilowicz, Sabrina Diez, Patricia Fainstein Day, Natalia García-Basavilbaso, Mariela Glerean, Mirtha Guitelman, Débora Katz, Monica Graciela Loto, Marcela Martinez, Karina Miragaya, Daniel Moncet, Amelia Susana Rogozinski, Marisa Servidio, Graciela Stalldecker
OBJETIVE: The aim was to assess the evolution of tumor size and prolactin (PRL) levels in patients with micro and macroprolactinomas diagnosed and treated with dopamine agonists during fertile age, and the effects of suspension of drugs after menopause. SUBJECTS AND METHODS: Retrospective study, 29 patients with prolactinomas, 22 microadenomas and 7 macroadenomas, diagnosed during their fertile age were studied in their menopause; treatment was stopped in this period...
February 2016: Archives of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/26830552/withdrawal-of-dopamine-agonist-therapy-in-prolactinomas-in-which-patients-and-when
#15
Sema Ciftci Dogansen, Ozlem Soyluk Selcukbiricik, Seher Tanrikulu, Sema Yarman
PURPOSE: The aim of the study was to assess the effect of dopamine agonist (DA) withdrawal, the current recurrence rate of hyperprolactinemia, and possible factors that predict recurrence in patients with prolactinoma. METHODS: We evaluated DA withdrawal in 67 patients with prolactinoma (50 female/17 male) who received DA treatment for at least 2 years and showed normalization of prolactin (PRL) levels and tumor disappearance or ≥50 % tumor shrinkage, retrospectively...
June 2016: Pituitary
https://www.readbyqxmd.com/read/26820213/-current-diagnosis-and-treatment-of-hyperprolactinemia
#16
Virgilio Melgar, Etual Espinosa, Ernesto Sosa, María José Rangel, Dalia Cuenca, Claudia Ramírez, Moisés Mercado
Hyperprolactinemia is a frequent neuroendocrinological condition that should be approached in an orderly and integral fashion, starting with a complete clinical history. Once physiological causes such as pregnancy, systemic disorders such as primary hypothyroidism and the use of drugs with dopamine antagonistic actions such as metochlopramide have been ruled out, the most common cause of hyperprolactinemia is a PRL-secreting pituitary adenoma or prolactinoma. Prolactinomas are usually classified as microprolactinomas (less than 1 cm) or macroprolactinomas (larger than 1 cm), which can either be confined or invasive...
January 2016: Revista Médica del Instituto Mexicano del Seguro Social
https://www.readbyqxmd.com/read/26682970/gender-differences-in-macroprolactinomas-a-single-centre-experience
#17
Shruti Khare, Anurag R Lila, Hiren Patt, Chaitanya Yerawar, Manjunath Goroshi, Tushar Bandgar, Nalini S Shah
Macroprolactinomas are the most common functional pituitary tumours. Hypotheses proposed to explain predominance of large tumours in males are: i) diagnostic delay, as hyperprolactinaemia remains under recognised in males and ii) gender-specific difference in tumour proliferation indices. Our study objectives are to compare gender differences in clinical, biochemical, radiological features, management outcomes and cabergoline responsiveness in macroprolactinomas. Drug resistance was defined as failure to achieve prolactin normalisation and >50% reduction in tumour volume with cabergoline (3...
January 2016: Endocrine Connections
https://www.readbyqxmd.com/read/26662655/macular-amyloidosis-complicating-macroprolactinoma-a-novel-clinical-association
#18
Deep Dutta, Arvind Ahuja, Lokesh Sharma, Minakshi Bhardwaj, Bindu Kulshreshtha
Amyloid deposition in the pituitary gland is a rare localised form of amyloidosis, and most commonly reported with prolactinoma. Macular amyloidosis is a rare form of localised cutaneous amyloidosis of obscure aetiology. In contrast to most localised amyloidosis, the precursor protein(s) of both macular amyloidosis and prolactinoma are unknown. A 35-year-old man with chronic headache (six years), blurring of vision (three years), and hyperpigmented macular lesion involving arms, legs, and back (two years) was diagnosed to have hyperprolactinaemia (8927 ng/mL) and secondary adrenal insufficiency...
2015: Endokrynologia Polska
https://www.readbyqxmd.com/read/26607296/expression-profiles-of-somatostatin-dopamine-and-estrogen-receptors-in-pituitary-adenomas-determined-by-means-of-synthetic-multilocus-calibrators
#19
Monika Drastikova, Martin Beranek, Filip Gabalec, David Netuka, Vaclav Masopust, Tomas Cesak, Josef Marek, Vladimir Palicka, Jan Cap
AIMS: Pituitary adenomas (PA) are non-invasive benign tumors with a high autopsy prevalence. They are classified according to the type of hormone secreted (prolactin, growth hormone, adrenocorticotropin, thyrotropin, folitropin, or luteinizing hormone). Clinically non-functioning adenomas (CNFA) lacking the typical hypersecretion of hormones make up a significant portion of PA. The aim of the study was to determine the complete expression profiles of somatostatin receptors (SSTR1-SSTR5), dopamine receptors type 2 (D2R), and estrogen receptors (ER1) in various types of PA...
June 2016: Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
https://www.readbyqxmd.com/read/26600054/should-free-thyroxine-go-back-into-the-routine-thyroid-profile
#20
M Livingston, P J Twomey, A Basu, S Smellie, J W Kane, A Heald
BACKGROUND: Many clinical chemistry laboratories offer thyroid-stimulating hormone (TSH) alone as a first-line test of thyroid function, and only reflex a free thyroxine (fT4) test if the TSH result is abnormal (i. e., outside of the laboratory reference range). In secondary hypothyroidism, a low fT4 may be accompanied by a low or a normal TSH level. A testing strategy that measures baseline TSH only risks missing cases of secondary hypothyroidism in which the TSH level is normal. METHODS: The current authors examined 26,106 consecutive thyroid function test (TFT) results in our initial analysis...
November 2015: Experimental and Clinical Endocrinology & Diabetes
keyword
keyword
59456
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"